Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой?
- Авторы: Синопальников А.И1
-
Учреждения:
- Российская медицинская академия непрерывного профессионального образования
- Выпуск: Том 26, № 5 (2019)
- Страницы: 47-60
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/297599
- DOI: https://doi.org/10.18565/pharmateca.2019.5.47-60
- ID: 297599
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
В статье представлены клинические рекомендации по применению оптимальной эмпирической антибактериальной терапии больных инфекциями нижних дыхательных путей (ИНДП), основанные на соответствующей доказательной базе и адаптированные к тому или иному региону с учетом знания структуры локальной антибиотикорезистентности ключевых пневмотропных возбудителей. В этом контексте главной задачей рекомендаций наряду с очерчиванием ключевых диагностических и дифференциально-диагностических признаков ИНДП становится и внедрение в повседневную клиническую практику рационального применения антибиотиков, а именно отказ от их назначения при вирусных/предположительно вирусных инфекций дыхательных путей и удержание от использования менее эффективных из них там, где антибактериальная терапия показана.
Полный текст
Об авторах
А. И Синопальников
Российская медицинская академия непрерывного профессионального образования
Email: aisyn@list.ru
Список литературы
- Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095-128. doi: 10.1016/S0140-6736(12)61728-0.
- Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;80:2224-60. doi: 10.1016/S0140-6736(12)61766-8.
- Murray C.J., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2197-2223. doi: 10.1016/S0140-6736(12)61689-4.
- Fleming-Dutra K.E., Hersh A.L., Shapiro D.J., et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 2016;315:1864-73. doi: 10.1001/jama.2016.4151.
- Bartlett J.G. Management of respiratory tract infections. 2nd ed. Lippincott Williams & Wilkins. Philadelphia, 1999.
- Kraus E.M., Pelzl S., Szecsenyi J., Laux G. Antibiotic prescribing for acute lower respiratory tract infections (LRTI) - guideline adherence in the German primary care setting: An analysis of routine data. PLoS One. 2017;12(3):e0174584. doi: 10.1371/journal.pone.0174584.
- McCullogh A.R., Pollack A.L., Hansen M.P, et al. Antibiotics for acute infections in general practice: comparison of prescribing rates with guideline recommendations. Med J Aust. 2017;207:65-9.
- Harbarth S., Balkhy H.H., Goossens H., et al. Antimicrobial resistance: one world, one fight! Antimicrob Resist Infect Control. 2015;4:49. doi: 10.1016/j.jgar.2016.10.013.
- Zumla A., Memish Z.A., Maeurer M., et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet. Infect. Dis. 2014;14:1136-49. doi: 10.1016/S1473-3099(14)70828-X.
- Appelbaum PC. 2012 and beyond: potential for start of a second pre-antibiotic era? J Antimicrob Chemother. 2012;67:2062-68. Doi: 10.1093/ jac/dks213.
- Gould I.M., Bal A.M. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4:185-91. doi: 10.4161/viru.22507.
- Ball P, Baquero F., Cars O., et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:37-40.
- Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient department, and emergency departments, United States, 1997. Vital and Health Statistics, Series 10. Hyattsville, MD: National Center for Health Statistics; 1999. DHHS publications no. (PHS). 2000. 1714 p.
- Llor C. Acute bronchitis: aetiology and treatment. Eur. Respir. Monogr. 2010;60:1-17.
- Macfarlane J., Holmes W., Gard P., et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56:109-14.
- Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1108-80.
- Benninger M., Segreti J. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J. Fam Prac. 2008;57(2):5-11.
- Breath sounds. From basic science to clinical practice. Eds. Priftis K.N., Hadjileontiadis L.J., Evard M.L. Springer International Publishing AG; Cham, Switzeland. 2018.
- Синопальников А.И., Козлов Р.С. Внебольничные инфекции дыхательных путей. Руководство для врачей. М., 2007. 352 с.
- Claessens Y.E., Debray M.P., Tubach F., et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J. Respir Crit Care Med. 2015;192:974-82. doi: 10.1164/rccm.201501-00170C
- Aqassandjan M., Shurin G.V., Ma Y., Shurin M.R. C-reactive protein and lung diseases. Int J. Biochem. Cell Biol. 2014;50:77-88.
- Brink A.J., Van Wyk J., Moodley V.M., et al. The role of appropriate diagnostic testing in acute tract infections: an antibiotic stewardship strategy to minimize diagnostic uncertainty in primary care. S. Afr Med J. 2016;106:00-7.
- Wark P. Bronchitis (acute). BMJ. Clin Evid. 2015;7:1508-06.
- 0tt S.R., Rohde G., Lepper P.M., et al. The impact of viruses in lower respiratory tract infections of the adult. Part II: acute bronchitis, acute exacerbated C0PD, pneumonia, and influenza. Pneumologie. 2010;64:18-27. doi: 10.1055/s-0029-1215197.
- Martinez F.J. Acute bronchitis: state of the art diagnosis and therapy. Compr Ther. 2004; 00:55-69.
- Liapikou A., Torres A. The clinical management of lower respiratory tract infections. Exp Rev Respir Med. 2016;10:441-52.
- Rohani P., Drake J.M. The decline and resurgence of pertussis in the US. Epidemics. 2011;0:180-88. doi: 10.1016/j.epidem.2011.10.001.
- Masseria C., Krishnarajah G. The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010. BMC. Infect. Dis. 2015;15:504. doi: 10.1186/s12879-015-1269-1.
- Gerber J.S. Improving Outpatient Antibiotic Prescribing: Another Nudge in the Right Direction. JAMA. 2016;015:558-59. Doi: 10.1001/ jama.a016.0430.
- Evertsen J., Baumgardner D.J., Regnery A., et al. Diagnosis and management of pneumonia and bronchitis in outpatient primary care practices. Prim Care Respir J. 2010;19:207-41. doi: 10.4104/pcrj.2010.00024.
- Harris A.M., Hicks L.A., Qaseem A., et al. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2013;134:425-04. Doi: 10.702 6/M15-1840
- Smith S.M., Fahney T., Smucny J., Becker L.A. Antibiotic for acute bronchitis (Review). Cochrane Database Syst Rev. 2017;6:CD 000245. doi: 10.1002/14651858.CD000245.pub4
- Harris A.M., Hicks L.A., Qaseem A., et al. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2013;134:425-04. Doi: 10.702 6/M15-1840
- Tan T., Little P, Stokes T. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ. 2008;007:a407. doi: 10.1106/bmj.a407
- www.nice.org.uk/CG069 (accessed 28 October 2015)
- Козлов РС., Зырянов С.К., Синопальников А.И., Рязанцев С.В. Эмпирическая антибактериальная терапия инфекций дыхательных путей с учетом факторов риска резистентной флоры. Резолюция совета экспертов. Справочник поликлинического врача. 2018;1:3-10
- Altunaiji S., Kukuruzovic R., Curtis N., Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007;0:CD004404
- Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Sem Respir Infect. 1999;14:151-62
- Hoyert D.L., Xu J. Death: preliminary data for 2011. Natl VitalStat Rep. 2012;31:1-51
- Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60:759-76.
- Ewig S., Birkner N., Strauss R., et al. New perspectives on community-acquired pneumonia in 088 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009764:1062- 69. Doi: 10.1106/ thx.2008.109785.
- Cilloniz C., Rodriguez-Hurtado D., Torres A. Characteristics, and management of community-acquired pneumonia in the era of global aging. Med Sci. 2018;3:05-52. Doi: 10.0090/ medsci6020005.
- Cilloniz C., Ardanuy C., Vila J., Torres A. What is the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2013;22:227-04. doi: 10.1097/MCP0000000000000232.
- Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012767:71-9. Doi: 10.1106/ thx.2009.129502.
- Herrero S.F., Olivas B. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med. 2012;00:220-01.
- Musher D.M., Abers M.S., Bartlett J.G. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis. 2017;65:1706-44. doi: 10.1090/cid/cix549.
- Marchello C., Dale A.P., Thai T.N., et al. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: av metaanalysis. Ann Fam Med. 2016;14:552-66.
- Cilloniz C., Torres A., Niederman M., et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med. 2016;42:1374-86. doi: 10.1007/s00104-016-4094-4.
- Внебольничная пневмония. Клинические рекомендации (проект), 2018. www.antibiotic. ru.
- Gleason PP, Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 1999;159:253272.
- Meehan T.P, Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080-84.
- Houck PM, Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637-44.
- Bjerre L.M., Verheij T.J., Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;4:CD002109. doi: 10.1002/14651858. CD002109.pub3.
- Torumkuney D., Mayanskiy N., Edelstein M., et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia. J Antimicrob Chemother. 2018;73(5):14-21. Doi: 10.1093/ jac/dky065.
- Cherazard R., Epstein M., Doan T.L., et al. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther. 2017;24:361 69. doi: 10.1097/MJT.0000000000000551
- Wiersinga W.J., Bonten M.J., Boersma W.G., et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth Med J. 2018;76:4-13.
- Boyles T.H., Brink A., Calligaro G.L., et al. South Africa guideline for the management of community-acquired pneumonia in adults. J ThoracDis. 2017;9:1469-502. Doi: 10.21037/ jtd.2017.05.31.
- Garin N., Genne D., Carballo S., et al. в-Lactam monotherapy vs в-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA. Intern. Med. 2014;174:1894-901. doi: 10.1001/jamainternmed.2014.4887.
- Ranzani O.T., Taniguchi L.U., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr Opin Pulm Med. 2018;24:227-36. Doi: 10.1097/ MCP.0000000000000468.
- Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:233-24.
- Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
- Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect. Dis. 2007;44(2):27-72.
- Charles PG., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375-84. doi: 10.1086/589754.
- Espana PP, Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174:1249-56.
- Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10. Doi: 10.1001/ jama.2016.0287.
- Zhang YQ., Zou S.L., Zhao H., et al. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. Am J Emerg Med. 2018;36(10):1759-65. doi: 10.1016/j:ajem.2018.01.079.
- Raz-Pasteur A., Shasha D., Paul M. Fluoroquinolones or macrolides alone versus combined with в-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Int J Antimicrob Agents. 2015;46:242-48. Doi: 10.1016/j. ijantimicag.2015.04.010.
- Ruhe J., Mildvan D. Does empirical therapy with a fluoroquinolone or the combination of a в-lactam plus a macrolide result in better outcomes for patients admitted to the general ward? Infect Dis Clin North Am. 2013;27:115-32. doi: 10.1016/j.idc.2012.11.004.
- Postma D.F., van Werkhoven C.H., van Elden L.J., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312-23. Doi: 10.1056/ NEJMoa1406330.
- Hajj E.L., Turgeon R.D., Wilby K.J. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review. Int J Clin Pharm. 2017;39:26-32. doi: 10.1007/s11096-016-0417-z.
- Ortiz-Ruiz G., Vetter N., Isaacs R., et al. Ertapenem versus for the treatment of community-acquired pneumonia in adults: combined analysis of two multicenter randomized, double-blind studies. J Antimicrob Chemother. 2004;53(2):ii59-66.
- Murcia J.M., Gonzales-Comeche J., Marin A., et al. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clin Microbiol Infect. 2009;15:1046-50. doi: 10.1111/j.1469-0691.2009.02843.x.
- Lisboa T., Salluh J.L., Friedman G. Macrolides and respiratory infection in critically ill patients: what is the next step? Minerva Anestesiol. 2016;82:221-29.
- Horita N., Otsuka T., Haranaga S., et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirol. 2011:1193-2000. Doi: 10.1111/ resp.12835.
- ЧучалинА.Г., Синопальников А.И., Козлов РС. и др. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых, 2014 (www. pulmonology.ru).
- Global initiative for Chronic Obstructive Lung Disease. GOLD Report 2018 (www.copdgold. com).
- Seemungal T.A., Donaldson G.C., Bhowmik A., et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 9000;121:1208-13.
- Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., et al. Severe acute exacerbations and mortality in patients with COPD. Thorax. 9005;20:995-31.
- Almagro P, Calbo E., Ochoahe Echaguen A., et al. Mortality after hospitalized for COPD. Chest. 9009;191:1441-48.
- Bafadhel M., McKenna S., Terry S., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 9011;184:229-71. Doi: 10.1164/ rccm.901104-05970c.
- GeorgeS.N., Garcha D.S., MackayA.J.,et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014;44:87 96. doi: 10.1183/09031932.00993113
- Siddiqi A., Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Intern J COPD. 2008;3:31-44.
- Allegra L., Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 9000;99:749-47.
- Eller J., Ede A., Schaberg T., et al. Infective exacerbations of chronic bronchitis: relation between bacterial etiology and lung function. Chest. 1998;113:1549-48.
- Lode H., Allewelt M., Balk S., et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection. 2007;05:140-49.
- Monso E., Garcia-Aymerich J., Soler N., et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2000;101:799-804.
- Garcia-Vidal C., Almagro P, Romani V, et al. Pseudomonas aeruginosa in patients hospitalized for COPD exacerbation: a prospective study. Eur Respir J. 2009;04:1072-78.
- Miravitlles M., Espinosa C., Fernandez-Laso E., et al. Study Group of bacterial infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-6.
- Gallego M., Pomares X., Espasa M., et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC. Pulm Med. 2014;14:100. doi: 10.1183/1471-2433-14-100.
- Anthonisen N.R., Manfreda J., Warren C.P, et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987;103:193-204.
- Puhan M.A., Vollenweider D.J., Latshang T., Steurer-Stey C.A. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007;8:00.
- Vollenweider D.J., Jarrett H., Steurer-Stey C.A., et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;12:CD010257. doi: 10.1002/14351858.CD010257.
- National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic pulmonary obstructive disease in adults in primary and secondary care (partial update). London, National Clinical Guideline Centre, 2004.
- Wedzicha J.A., Miravitlles M., Hurst J.R., et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1300791. doi: 10.1180/10990000.00791-2013.
- Stockley R.A., O'Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1308-45.
- Miravitlles M., Kruesmann F, Haverstock D., et al. Sputum color and bacteria in chronic bronchitis exacerbations: A pooled analysis. Eur Respir J. 2012739:1354-60. doi: 10.1180/09001903.00042111.
- Soler N., Agusti C., Angrill J., et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29-05.
- Llor C., Moragas A., Hernandez S., et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate COPD. Am J Respir Crit Care Med. 2012;183:713-20. Doi: 10.1164/ rccm.201203-09930C.
- Celli B.R., MacNee W., ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004;20:902-46.
- Feldman C., Richards G. Appropriate antibiotic management of bacterial lower respiratory tract infections. F1000 Research. 2018;7:1121. doi: 10.12388/f1000research.14223.1.
- Woodhead M., Blasi F, Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect. 2011;17(6):1-59. doi: 10.1111/j.1469-0391.2011.00372.x.
- Rothberg M.B., Pekow PS., Lahti M., et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;000:2005-42. Doi: 10.1001/ jama.2010.372.
- Miravitlles M., Murio C., Guerrero T., et al. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:928-00.
- Wilson R., Schentag J.J., Ball P, Mandell L., 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:609-52.
- Wilson R., Allegra L., Huchon G., et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest.
- Ruiz-GonzalezA.,GimenezA., Gomez-ArbonesX., et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology. 2007;12:117-21.
- Miravitlles M., Anzueto A. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 22137l88:1252-7. doi: 10.1134/rccm.201002-0289PP.